Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation (PEGorion)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00603681
Recruitment Status : Completed
First Posted : January 29, 2008
Last Update Posted : October 7, 2008
Information provided by:
Orion Corporation, Orion Pharma

Brief Summary:
The aim of the study is to show that new polyethylene glycol (PEG) solution without electrolytes is as effective in the treatment of constipation as PEG solution with electrolytes in the elderly institutionalized people. Also, the tolerability and the safety of the study drug will be examined.

Condition or disease Intervention/treatment Phase
Constipation Drug: Polyethylene glycol 4000 Drug: Polyethylene glycol 4000 with electrolytes Phase 4

Detailed Description:

Constipation is a major problem in elderly institutionalised patients. Non-pharmacological treatments are proposed as primary management of constipation, but institutionalised patients are not likely to be able to increase either the intake of dietary fibre or fluid and their physical activity is low.

The latest agent widely used for the treatment of constipation is polyethylene glycol (PEG). PEG is classified into the group of osmotic laxatives. It is minimally absorbed from the gastrointestinal tract and not metabolised by colonic bacteria.

Most of the PEG products at the market contain electrolytes and have a salty and unpleasant taste which may affect the compliance of using them. A PEG solution without electrolytes has been developed and used for some years in various countries. Now we will compare the efficacy and safety of PEG solutions with or without electrolytes and their acceptability in the use for constipation in institutionalised patients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Non-Inferiority Study; Comparison of Polyethylene Glycol Solution With and Without Electrolytes for Treatment of Chronic Constipation in Elderly Institutionalised Patients: a Double-Blind, Randomised, Parallel-Group, Multicentre Study
Study Start Date : January 2008
Primary Completion Date : July 2008
Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
U.S. FDA Resources

Arm Intervention/treatment
Experimental: T
Test product
Drug: Polyethylene glycol 4000
powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
Other Name: Pegorion
Active Comparator: C
Reference product
Drug: Polyethylene glycol 4000 with electrolytes
granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
Other Name: Colonsoft

Primary Outcome Measures :
  1. Stool frequency [ Time Frame: week 4 ]

Secondary Outcome Measures :
  1. Stool frequency [ Time Frame: Week 2 ]
  2. Stool straining [ Time Frame: Weeks 2 and 4 ]
  3. Stool consistency [ Time Frame: Weeks 2 and 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Isotonic PEG treatment for constipation at the stable dose for at least 2 weeks before the run-in period

Exclusion Criteria:

  • Other medical treatment for constipation than isotonic PEG or plantago ovata seeds
  • Severe dementia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00603681

Tampere, Finland, 33100
Tampere, Finland, 33500
Tampereen sotainvalidien Veljeskoti
Tampere, Finland, 33500
Lahdensivun koti
Tampere, Finland, 33560
Tampere, Finland, 33680
Vire Koti Kaukaharju assisted-living facility
Tampere, Finland, 33710
Taatala assested-living facility
Tampere, Finland, 33820
Kuusela assisted-living facility
Tampere, Finland, 33900
Tampere, Finland, 33900
Nursing home of Tiuravuori
Ylöjärvi, Finland, 33480
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Principal Investigator: Lauri Seinelä, MD Pirkanmaan erikoislääkäripalvelu Oy
Study Director: Ulla Sairanen, MSc Orion Corporation, Orion Pharma

Responsible Party: Ulla Sairanen, Orion Pharma Identifier: NCT00603681     History of Changes
Other Study ID Numbers: 3066001
First Posted: January 29, 2008    Key Record Dates
Last Update Posted: October 7, 2008
Last Verified: October 2008

Keywords provided by Orion Corporation, Orion Pharma:
polyethylene glycol

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Pharmaceutical Solutions